Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Penelope MacRae
Magellan Rx has launched a program to encourage a shift to lower-cost oncology biosimilars, ahead of their US market entry this year, building on what the PBM says has been a successful drive for some autoimmune conditions to be treated with biosimilar versions of infliximab.
Sun releases what it says are promising interim data from a Phase II study on Ilumya, its flagship first novel biologic, in the additional indication of psoriatic arthritis, where the antibody met the primary endpoint in its first trial in this setting.
An Oklahoma judge is withholding approval of the state’s proposed $85m out-of-court opioid settlement with Teva until he gets assurances that it complies with state law.
Three companies are in the race to take over bankrupt Orchid Pharmaceuticals under a new round of bidding being held for the generic drugmaker after a previous takeover deal collapsed.
Analysts said more challenges lie ahead for Zydus Cadila that will hobble earnings growth over the next couple of years, after the Indian firm reported a more than 20% slide in quarterly profit.
India's Aurobindo says it is betting its $1bn purchase of Sandoz' US dermatology assets will help “really fuel growth” and that the company's biggest acquisition should be wrapped up in eight to 12 weeks.